Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study.
Previous studies of blood pressure and mortality in haemodialysis have yielded mixed results, perhaps due to confounding by comorbid conditions. We hypothesized that after improved accounting for confounding factors, higher systolic blood pressure (SBP) would be associated with higher all-cause mortality. We conducted a secondary analysis of data from the haemodialysis study, a randomized trial in prevalent haemodialysis patients. We used three proportional hazard models to determine the relative hazard at different levels of SBP: (1) Model-BL used baseline SBP; (2) Model-TV used SBP as a time-varying variable; and (3) Model-TV-Lag added a 3-month lag to Model-TV to de-emphasize changes in SBP associated with acute illness. In all the models, pre-dialysis SBP <120 mm Hg was associated with a higher risk of mortality compared with the referent group (140-159 mm Hg); higher pre-dialysis SBP was not associated with higher risk of mortality. In conclusion, we observed a robust association between lower pre-dialysis SBP and higher risk for all-cause and cardiovascular mortality in a well-characterized cohort of prevalent haemodialysis patients. Randomized clinical trials are needed to define optimal blood pressure targets in the haemodialysis population.
Chang
T I
TI
Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA 94304, USA. tichang@stanford.edu
Friedman
G D
GD
Cheung
A K
AK
Greene
T
T
Desai
M
M
Chertow
G M
GM
D000704:Analysis of Variance; D001794:Blood Pressure; D001795:Blood Pressure Determination; D015897:Comorbidity; D015986:Confounding Factors, Epidemiologic; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000401:mortality*; D012307:Risk Factors; D013997:Time Factors
Kidney Int. 1998 Aug;54(2):561-9
9690224
Hypertension. 2010 Mar;55(3):762-8
20083728
JAMA. 2002 Mar 27;287(12):1548-55
11911757
JAMA. 2003 May 21;289(19):2560-72
12748199
Kidney Int. 2000 Nov;58(5):2147-54
11044236
Lancet. 2009 Mar 21;373(9668):1009-15
19249092
Kidney Int. 2005 Jan;67(1):1-13
15610223
Am J Kidney Dis. 2006 Oct;48(4):606-15
16997057
N Engl J Med. 2001 Nov 1;345(18):1291-7
11794147
N Engl J Med. 2002 Dec 19;347(25):2010-9
12490682
Clin J Am Soc Nephrol. 2009 May;4(5):914-20
19357245
Nephrology (Carlton). 2009 Apr;14(3):283-90
19444959
Kidney Int. 2002 Feb;61(2):717-26
11849415
Am J Kidney Dis. 2005 Apr;45(4 Suppl 3):S1-153
15806502
Heart. 2009 Jan;95(1):56-62
18653573
Kidney Int. 2002 Nov;62(5):1784-90
12371980
Am J Kidney Dis. 2002 Jun;39(6):1226-30
12046035
BMJ. 1989 Jun 10;298(6687):1552-6
2503114
Kidney Int. 2008 Mar;73(6):759-64
18160959
Am J Kidney Dis. 2002 Feb;39(2):227-44
11840363
Hypertension. 2009 May;53(5):860-6
19273737
Lancet. 2002 Dec 14;360(9349):1903-13
12493255
Kidney Int. 2001 Oct;60(4):1498-510
11576365
Control Clin Trials. 2000 Oct;21(5):502-25
11018567
J Am Soc Nephrol. 2006 Feb;17(2):513-20
16396968
Kidney Int. 1996 May;49(5):1379-85
8731103
Clin J Am Soc Nephrol. 2006 May;1(3):389-98
17699236
Am J Kidney Dis. 1999 Mar;33(3):507-17
10070915
Am J Kidney Dis. 2002 Jan;39(1):146-53
11774113